Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | PHF13 | Q86YI8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858409 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL17108786 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL17108787 | 0.96 | SMN1; SMN2 (0.50) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL27969917 | 0.84 | CHRNB2 (0.47) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL29934322 | 0.84 | HRH3 (0.47) | SMN1; SMN2HRH3KDM4EALDH1A1PRMT6 | |
| SCHEMBL23501608 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2TDP1KDM4EALDH1A1TSHR | |
| SCHEMBL112800 | 0.84 | MC4R (0.47) | SMN1; SMN2TDP1KDM4EALDH1A1PRMT6 | |
| SCHEMBL29933818 | 0.84 | MC4R (0.47) | SMN1; SMN2TDP1KDM4EALDH1A1PRMT6 | |
| SCHEMBL29934142 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2TDP1KDM4EALDH1A1TSHR | |
| SCHEMBL114033 | 0.84 | HRH3 (0.47) | SMN1; SMN2HRH3KDM4EALDH1A1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-112135821-B | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | 方济各安吉利克化学联合股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007083017-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | WO | disclosed |
| EP-0871615-B1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6194581-B1 | FOR TREATMENT OF DYSFUNCTION OF THE CENTRAL OR AUTONOMIC NERVOUS SYSTEMS INCLUDING DEMENTIA, COGNITIVE DISORDERS, NEURODEGENERATIVE DISORDERS, EXTRAPYRAMIDAL DISORDERS, CONVULSIVE DISORDERS, CARDIOVASCULAR DISORDERS, PAIN | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| US-5852041-A | Substituted pyridines useful as modulators of acethylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0871615-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5736560-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S AND PARKINSONS'S DISEASES | SIBIA NEUROSCIENCES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5686473-A | TREATING PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, DEMENTIA AND PAIN | SIBIA NEUROSCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5585388-A | Substituted pyridines useful as modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996031475-A2 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | SMN1; SMN2 3885/4885TDP1 3035/4885CHRNB2 1504/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | SMN1; SMN2 3316/4885TDP1 498/4885CHRNB2 2006/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | SMN1; SMN2 3885/4885TDP1 3035/4885CHRNB2 1504/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | SMN1; SMN2 2736/4885TDP1 3518/4885CHRNB2 2478/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | SMN1; SMN2 2603/4885TDP1 3553/4885CHRNB2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.